Navigation Links
MacuSight(TM) Announces Positive Preliminary Results From Phase 1 Study of Sirolimus in Wet Age-Related Macular Degeneration
Date:2/25/2008

Sirolimus Demonstrates Favorable Safety Profile and Improvements in Visual

Acuity

UNION CITY, Calif., Feb. 25 /PRNewswire/ -- MacuSight(TM), Inc., a developer of innovative therapeutics for the treatment of severe ocular diseases and conditions, today announced positive preliminary data from a Phase 1 study of its lead product candidate in patients with wet (exudative) age-related macular edema (wet AMD). Similar to its Phase 1 study in patients with diabetic macular edema (DME), preliminary results from this prospective study of 30 patients demonstrated that MacuSight's proprietary formulation of sirolimus (rapamycin) was safe and well-tolerated in all doses tested with two different routes of administration. In addition, improvements in visual acuity consistent with anatomical retinal changes were observed following a single administration of sirolimus. These findings were presented at Bascom Palmer Eye Institute's Angiogenesis, Exudation and Degeneration 2008 conference by Pravin U. Dugel, M.D., member of MacuSight's scientific advisory board, managing partner, Retinal Consultants of Arizona, Phoenix AZ, clinical instructor, vitreoretinal diseases and surgery, department of ophthalmology, University of Arizona, and the study's lead investigator.

As part of the design of this randomized, open-label study, investigators evaluated the safety, tolerability and biological activity of sirolimus when delivered by either a subconjunctival or intravitreal injection. The trial showed no evidence of increased intraocular pressure, inflammatory response to treatment, or indication of progression of cataracts. Furthermore, the study provided an initial assessment of sirolimus' biological activity in AMD with patients demonstrating improvements in visual acuity despite extended duration of disease prior to entering the study. Additionally, patients also experienced anatomical improvements as demonstrated by a reduction in
'/>"/>

SOURCE MacuSight, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. MacuSight(TM) Announces Positive Initial Results From Phase 1 Study of Sirolimus in Diabetic Macular Edema
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Revenue and earnings above the previous year - ... In the past 2013/14 fiscal year (ended 30 September ... 4.287 billion (last year: EUR 4.190 billion) despite unfavorable currency ... million. "Overall, 2013/14 was a successful fiscal year for the ... CEO of Carl Zeiss AG. "Thanks to our broad portfolio ...
(Date:12/17/2014)... , Dec. 17, 2014 With ... (MRI), the MRI market is seeing new growth, ... breast MRI scans account for the majority of ... higher resolution of images, which are creating opportunities for ... (MRI) market is growing at a rate of ...
(Date:12/17/2014)... 17, 2014  ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE ... Trademark Office (USPTO) has issued a key patent ... immunotherapeutic vaccine targeting six tumor antigens that are ... Patent No. 8,871,211, which issued October 28, 2014, ... a dendritic cell composition comprising peptide epitopes of ...
Breaking Medicine Technology:ZEISS Asserts its Position in Difficult Environment 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2
... 2011 Actavis Group, the international generic pharmaceuticals company, today ... a binding letter of intent (LOI) with QRxPharma Limited (ASX: ... United States.  Under the terms of the ... IR, a patented 3:2 ratio fixed dose combination of morphine ...
...  QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today execution ... for the formation of a strategic partnership to commercialise MoxDuo ... IR is a patented 3:2 ratio fixed dose combination of ... Group, hf a privately held company based in Europe with ...
Cached Medicine Technology:Actavis to Launch Novel Pain Medication in the US 2Actavis to Launch Novel Pain Medication in the US 3QRxPharma Announces Strategic Partnership with Actavis 2QRxPharma Announces Strategic Partnership with Actavis 3QRxPharma Announces Strategic Partnership with Actavis 4QRxPharma Announces Strategic Partnership with Actavis 5
(Date:12/21/2014)... FL (PRWEB) December 21, 2014 When families ... lice, who do they call? The new answer is ... Coral Gables FL 33134, their newest treatment center will be ... pest quickly, conveniently and without the use of harmful chemicals ... is scheduled for January 1, 2015. Like the company’s first ...
(Date:12/21/2014)... 2014 The number of Mirena lawsuits ... litigation underway in New Jersey, Bernstein Liebhard LLP reports. ... claims involving the birth control IUD have now been ... filed by women who allege spontaneous migration of the ... perforations and other complications they were inadequately warned about ...
(Date:12/21/2014)... SCI explores disability in sports this ... for disabled athletes with Aaron Scheidies , legally ... called juvenile macular degeneration, where he loses his central ... athletic ambitions to his vision and how he has ... the way for other blind and visually impaired athletes. ...
(Date:12/21/2014)... 2014 Concept Plus, LLC. a SDB ... in Fairfax, VA., today announced it has been recognized ... list, which ranks the fastest growing government contracting small businesses ... 2013. , This is the first year that Concept Plus, ... 20 with a 95.92% compound annual growth rate. “For Concept ...
(Date:12/20/2014)... New York, NY (PRWEB) December 20, 2014 ... with the healthcare sector have benefited the Massage ... Given the discretionary characteristics of industry products, the anticipated ... the five-year period has provided consumers with the means ... adults that have received a massage in a given ...
Breaking Medicine News(10 mins):Health News:All-Natural Florida Lice Removal Company Opens New Lice Treatment Salon In South Florida 2Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 3Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 2Health News:Disability in Sports on SCI TV with Triathlon World Champ Aaron Scheidies 3Health News:Concept Plus, LLC. Named One of Washington Technology’s Fast 50 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3
... , , SALT LAKE CITY, ... instrument company focused on unique silicon nitride ceramic technologies, announced today ... global headquarters. , , Bucking the national trend, ... the new larger multifunctional facility. Amedica believes the new space ...
... , , , , ... The Mount Sinai Medical Center has joined with Long Island Heart ... surgical cardiovascular care to patients on Long Island. , , ... Associates made it an ideal match for our cardiovascular center of ...
... , , CHICAGO, ... the H1N1 virus - the upcoming revisit of swine flu - ... plans within the private sector. "There,s no question that companies have ... are navigating a daunting market and obstacles not immediately in their ...
... , BOSTON, Sept. 10 Purchasers of ... a rollback of benchmark prices of some of the most ... affirmed the approval of a settlement with two leading drug-pricing ... Kluwer Health, Inc. , , (Logo: ...
... , , LOS ANGELES, Sept. 10 ... into DietTribe , Lifetime,s reality series about a group of friends ... premieres Friday, October 2nd at 9:00pm ET/PT . ... return to guide and coach an all-new tribe as they work towards ...
... CHICAGO, Sept. 10 The following is a statement by Lenore Janecek, ... As this debate rages on about medical reform, patient safety organizations, those of ... what is happening to the people from the senseless health care devastation throughout ... million people in the U.S. died needlessly in the past ten ...
Cached Medicine News:Health News:Amedica Announces New Global Headquarters 2Health News:Expanded Cardiovascular Care Services on Long Island 2Health News:H1N1 Swine Flu Preparedness Uncertainty Results in Higher Business Disruption Risk 2Health News:Major Rollback of Pharmaceutical Bench Mark Prices Approved by Federal Court of Appeals, Hagens Berman Announces 2Health News:Major Rollback of Pharmaceutical Bench Mark Prices Approved by Federal Court of Appeals, Hagens Berman Announces 3Health News:Major Rollback of Pharmaceutical Bench Mark Prices Approved by Federal Court of Appeals, Hagens Berman Announces 4Health News:Get Pumped Up for the Return of 'DietTribe' Season Two of Inspirational Lifestyle Series Premieres October 2 on Lifetime Television 2Health News:Get Pumped Up for the Return of 'DietTribe' Season Two of Inspirational Lifestyle Series Premieres October 2 on Lifetime Television 3Health News:Medical Holocaust in U.S.: Who in the Health Cares? 2Health News:Medical Holocaust in U.S.: Who in the Health Cares? 3
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
Medicine Products: